Goodman Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Goodman Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$962	–	204
2024 Q1	$962	Buy	+1	New	+$951	﹤0.01%	163
2023 Q2	–	Sell	-298	Closed	-$245K	–	179
2023 Q1	$245K	Sell	298 -412	-58%	-$311K	0.13%	44
2022 Q4	$512K	Hold	710	–	–	0.3%	35
2022 Q3	$489K	Sell	710 -179	-20%	-$113K	0.27%	36
2022 Q2	$526K	Sell	889 -6,287	-88%	-$4.09M	0.23%	33
2022 Q1	$5.01M	Sell	7,176 -1,002	-12%	-$634K	1.73%	20
2021 Q4	$5.17M	Buy	+8,178	New	+$5.03M	1.74%	21

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goodman Advisory Group's REGN Position: Q2 2024 in Review

Goodman Advisory Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 1 share — an estimated $962 sold.

Goodman Advisory Group first reported a position in REGN in Q4 2021 and held it in 7 quarters. The position peaked at $5.17M in Q4 2021. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

Goodman Advisory Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Goodman Advisory Group sold 1 Regeneron Pharmaceuticals share in Q2 2024, an estimated $962.
Goodman Advisory Group first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Goodman Advisory Group's Regeneron Pharmaceuticals position peaked at $5.17M in Q4 2021.
1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Goodman Advisory Group's 13F filing for Q2 2024, filed 15 Aug 2024.